PHILADELPHIA, May 16, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that results from multiple animal studies with the company’s Vaxfectin®-formulated plasmid DNA (pDNA) vaccines against herpes simplex virus type 2 (HSV-2) demonstrate proof of concept supporting the company’s decision in early 2012 to advance toward clinical testing, which is expected to begin in 2013. Results from completed prophylactic and therapeutic studies in mice and therapeutic studies in guinea pigs included:
